Aberdeen Group plc Reduces Holdings in Stryker Corporation $SYK

Aberdeen Group plc cut its position in Stryker Corporation (NYSE:SYK) by 6.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 308,666 shares of the medical technology company’s stock after selling 19,998 shares during the quarter. Aberdeen Group plc owned 0.08% of Stryker worth $114,169,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the company. Mid American Wealth Advisory Group Inc. purchased a new stake in shares of Stryker during the second quarter worth about $26,000. Clayton Financial Group LLC purchased a new position in Stryker in the third quarter valued at about $26,000. Elevation Point Wealth Partners LLC acquired a new stake in Stryker during the 2nd quarter valued at approximately $28,000. Kilter Group LLC purchased a new stake in Stryker during the 2nd quarter worth approximately $29,000. Finally, Howard Hughes Medical Institute acquired a new position in shares of Stryker in the 2nd quarter valued at approximately $29,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

SYK has been the topic of several recent analyst reports. Raymond James Financial raised shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price target on the stock in a report on Tuesday, January 6th. BTIG Research increased their price target on shares of Stryker from $410.00 to $412.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Wells Fargo & Company lifted their price target on Stryker from $452.00 to $456.00 and gave the stock an “overweight” rating in a research note on Friday, November 14th. Barclays restated an “overweight” rating and set a $469.00 price objective on shares of Stryker in a research note on Monday, February 2nd. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $435.00 target price on shares of Stryker in a research report on Friday, November 14th. Twelve analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $426.94.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the transaction, the director owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Preston Wendell Wells sold 165 shares of the business’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $365.88, for a total transaction of $60,370.20. Following the sale, the chief financial officer directly owned 6,694 shares in the company, valued at approximately $2,449,200.72. This trade represents a 2.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 5.90% of the stock is owned by insiders.

Stryker Stock Up 0.0%

Stryker stock opened at $366.02 on Friday. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $404.87. The stock has a market cap of $140.07 billion, a price-to-earnings ratio of 43.57, a PEG ratio of 2.14 and a beta of 0.87. The company’s 50-day moving average price is $358.00 and its two-hundred day moving average price is $369.35. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.40 by $0.07. The business had revenue of $7.17 billion during the quarter, compared to analysts’ expectations of $7.12 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The company’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the business posted $4.01 earnings per share. On average, analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s dividend payout ratio (DPR) is 41.90%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.